Company / PP&E (Net)
Oric Pharmaceuticals, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.4M
FY2025
5-year range
$2.4M / $3.3M
FY2021-FY2025
Trend
-17.4%
vs FY2024
Sector context
#128 of 193
Health Care
What the data says
At $2M, Oric Pharmaceuticals, Inc.'s pp&e (net) ranks #128 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 7 years, ranging from $2M in FY2020 to $3M in FY2022.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +4.0%.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -9.5%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
#128 of 193 in Health CareTop 66% of 193This company $2.4M Sector average $777.6M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 17.4% year-over-year.
- Ranks #128 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -17.4% |
| FY2024 | $2.9M | +2.2% |
| FY2023 | $2.9M | -12.0% |
| FY2022 | $3.3M | +34.8% |
| FY2021 | $2.4M | +21.8% |
| FY2020 | $2.0M | -11.6% |
| FY2019 | $2.2M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026